A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumoursEdwina N. Scott, Johann S. de Bono, Sarah P. Blagden et al.|Cancer Chemotherapy and Pharmacology|2009Cited by 34
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumoursAlastair Greystoke, William P. Steward, Sarah P. Blagden et al.|Annals of Oncology|2006Cited by 24